Praxis Medica
Sign in
Issue image

More articles from Volume 50, Issue 3, 2021

The role of the electrocardiogram in identifying the risk of sudden cardiac death

Prevalence, etiology and treatment of psychogenic aphonia in children: A case report

The effects of exertional heat stress on some complex cognitive functions

Why anatomical terminology in Serbian languange?

Effectiveness of coronavirus disease-19 vaccination on disease transmission, hospitalization, and clinical outcomes in adults in North India

Effectiveness of coronavirus disease-19 vaccination on disease transmission, hospitalization, and clinical outcomes in adults in North India

Kshitij Shah
Kshitij Shah
View authors publications

Search this author on:

PubMed | Google Scholar

Published: 01.12.2020.

Volume 50, Issue 3 (2021)

pp. 21-26;

https://doi.org/10.5937/pramed2104021d

Abstract

Background: Covaxin and Covishield vaccines have rapidly rolled out in India to curb the pandemic. We aimed to test the hypothesis that COVID-19 vaccination is clinically effective. Methods: This study was conducted in the Department of Physiology at MGM College, Jaipur, India after approval from the Ethics Committee. Vaccinated and non-vaccinated groups were tested on disease transmission, hospitalization, and clinical outcomes. Researchers collected data using questionnaires circulated through google forms. The association between attributes was tested using the chi-squared test. The significance level was considered at 5%. Results: The vaccination significantly reduced disease transmission of COVID-19 [c2=4.51; p = 0.034]. However, no significant differences were seen in RTPCR positivity, chest CT findings, and hospitalization on vaccination. COVID-related symptoms and their severity were not statistically different between the two groups. Most elderly were vaccinated [c2=41.68; p < 0.001]. Most youths took one dose, while the elderly took two doses of the vaccine [c2=41.77; p < 0.001]. All age groups had similar severity of AEFIs [c2=13.22; p < 0.21]. The vaccination status across gender did not differ significantly. [c2=1.13; p < 0.288] Most males took two doses as compared to females [c2=6,57; p < 0.01]. Adverse effects post-immunization were more severe in females than males [c2=13.10; p < 0.001]. There was no association between the number of vaccine doses and the severity of AEFIs [c2=16.42; p = 0.06]. Conclusion: The present study concludes the beneficial effect of vaccination in reducing disease transmission. However, vaccination has no role in mitigating other COVID-related outcomes.

References

1.
Zhou P, Lou YX, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin.
2.
Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Vol. 579, Nature. 2020. p. 265–9.
3.
Ciotti M, Ciccozzi M, Terrinoni A, Jiang WC, Wang CB, Bernardini S. The COVID-19 pandemic. Vol. 57, Critical Reviews in Clinical Laboratory Sciences. 2020. p. 365–88.
4.
Weekly epidemiological update on COVID-19. 2022.
5.
Tak A, Dia S, Dia M, Wehner T. Indian COVID-19 dynamics: Prediction using autoregressive integrated moving average modelling. Vol. 52, Scripta Medica. 2021. p. 6–14.
6.
Tak A, Bhandari S, Shaktawat A, Patel B, Gupta K, Gupta J, et al. A multistate ecological study comparing evolution of cumulative cases (trends) in top eight COVID-19 hit Indian states with regression modeling. Vol. 6, International Journal of Academic Medicine. 2020. p. 91.
7.
How Coronavirus Spreads | CDC.
8.
Masihi KN. Fighting infection using immunomodulatory agents. Vol. 1, Expert Opinion on Biological Therapy. 2001. p. 641–53.
9.
Evidence-based decision making and covid-19: what a posteriori probability distributions speak | Journal of Ideas in Health [Internet.
10.
Kakkar S, Bhandari S, Singh A, Sharma R, Mehta S, Gupta J, et al. Coronavirus disease of 2019: The premise for framing strategies towards infection prevention control management. Vol. 18, Current Medical Issues. 2020. p. 199.
11.
Bhandari S, Tak A, Singhal S, Shukla J, Shaktawat AS, Gupta J, et al. Patient Flow Dynamics in Hospital Systems During Times of COVID-19: Cox Proportional Hazard Regression Analysis. Vol. 8, Frontiers in Public Health.
12.
Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study.
13.
Basavaraja CK, Sebastian J, Ravi MD, John SB. Adverse events following COVID-19 vaccination: first 90 days of experience from a tertiary care teaching hospital in South India. Vol. 9, Therapeutic Advances in Vaccines and Immunotherapy. 2021. p. 251513552110558.
14.
Thathai A, Gahlot R, Gahlot NK, R B, Singh MM, Prakash P, et al. Study of COVID-19 Infection, its Severity and Outcome in COVID-19 Vaccinated People at Tertiary Health Care Center, North West Rajasthan. Vol. 1;69(9):11-2. 2021.
15.
Das S, Kar SS, Samanta S, Banerjee J, Giri B, Dash SK. Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review. Vol. 70, Immunologic Research. 2022. p. 289–315.
16.
Bhandari S, Shaktawat A, Tak A, Patel B, Shukla J, Singhal S, et al. Logistic regression analysis to predict mortality risk in COVID-19 patients from routine hematologic parameters. Vol. 12, Ibnosina Journal of Medicine and Biomedical Sciences. 2020. p. 123–9.
17.
Journal of the Association of Physicians of India.
18.
Bhandari S, Shaktawat A, Tak A, Shukla J, Gupta J, Patel B, et al. Relationship between ABO blood group phenotypes and nCOVID-19 susceptibility: A retrospective observational study. Vol. 51, Scripta Medica. 2020. p. 217–39.
19.
Bhandari S, Shaktawat AS, Patel B, Rankawat G, Tak A, Kumar Gupta J, et al. Hydroxychloroquine in Rheumatological Disorders: The Potential Buffer against Coronavirus Disease-19? Vol. 6, Journal of Medical Sciences and Health. 2021. p. 58–65.
20.
Bhandari S, Shaktawat AS, Tak A, Shukla J, Gupta J, Patel B, et al. Evaluating interactions between hyperglycemia and clotting factors in patients suffering with SARS-CoV-2 infection. Vol. 10, Clinical Diabetology. p. 114–22.
21.
Verma M, Sharma S, Kumar A, Hakim A, Bhansali S, Meena R. Comorbidities and Vaccination Status of COVID-19 All-Cause Mortality at a Tertiary Care Center of Western India. Cureus. 2022.
22.
Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. p. n1088.
23.
Ganneru B, Jogdand H, Daram VK, Das D, Molugu NR, Prasad SD, et al. Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation. Vol. 24, iScience. 2021. p. 102298.
24.
Ella R, Vadrevu KM, Jogdand H, Prasad S, Reddy S, Sarangi V, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Vol. 21, The Lancet Infectious Diseases. 2021. p. 637–46.
25.
Ella R, Reddy S, Jogdand H, Sarangi V, Ganneru B, Prasad S, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Vol. 21, The Lancet Infectious Diseases. 2021. p. 950–61.
26.
Ella R, Reddy S, Blackwelder W, Potdar V, Yadav P, Sarangi V, et al. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. 2021.
27.
Yadav D. Diagnostic tools for evaluating the effectiveness of COVID 19 vaccines: Challenges and solution. Vol. 10, Journal of Family Medicine and Primary Care. 2021. p. 2059.
28.
Bhandari S, Singh S, Tak A, Patel B, Gupta J, Gupta K, et al. Independent role of CT chest scan in COVID-19 prognosis: Evidence from the machine learning classification. Vol. 52, Scripta Medica. 2021. p. 273–8.
29.
Yadav PD, Ella R, Kumar S, Patil DR, Mohandas S, Shete AM, et al. Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques. Vol. 12, Nature Communications.
30.
Choudhary HR, Parai D, Chandra Dash G, Kshatri JS, Mishra N, Choudhary PK, et al. Persistence of Antibodies Against Spike Glycoprotein of SARS-CoV-2 in Healthcare Workers Post Double Dose of BBV-152 and AZD1222 Vaccines. Vol. 8, Frontiers in Medicine.
31.
Singh AK, Phatak SR, Singh R, Bhattacharjee K, Singh NK, Gupta A, et al. Humoral antibody kinetics with ChAdOx1-nCOV (CovishieldTM) and BBV-152 (CovaxinTM) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study. Vol. 16, Diabetes &amp; Metabolic Syndrome: Clinical Research &amp; Reviews. 2022. p. 102424.
32.
Bhattacharya A, Ranjan P, Ghosh T, Agarwal H, Seth S, Maher GT, et al. Evaluation of the dose-effect association between the number of doses and duration since the last dose of COVID-19 vaccine, and its efficacy in preventing the disease and reducing disease severity: A single centre, cross-sectional analytical study from India. Vol. 15, Diabetes &amp; Metabolic Syndrome: Clinical Research &amp; Reviews. 2021. p. 102238.
33.
Kamal D, Thakur V, Nath N, Malhotra T, Gupta A, Batlish R. Adverse events following ChAdOx1 nCoV-19 Vaccine (COVISHIELD) amongst health care workers: A prospective observational study. Vol. 77, Medical Journal Armed Forces India. 2021. p. S283–8.
34.
Sachdeva S, Saluja H, MANI A. Cognizance, adverse effects and motivation regarding COVID-19 vaccination amongst health care professionals: A cross-sectional study. Vol. 59, Dental and Medical Problems. p. 13–9.
35.
Arora G, Taneja J, Bhardwaj P, Goyal S, Naidu K, Yadav SK, et al. Adverse events and breakthrough infections associated with COVID-19 vaccination in the Indian population.
36.
Selvaraj P, Muthu S, Jeyaraman N, Prajwal GS, Jeyaraman M. Incidence and severity of SARS-CoV-2 virus post COVID-19 vaccination: A cross-sectional study in India. Vol. 14, Clinical Epidemiology and Global Health. 2022. p. 100983.
37.
Abhilash KPP, Mathiyalagan P, Krishnaraj VRK, Selvan S, Kanagarajan R, Reddy NP, et al. Impact of prior vaccination with CovishieldTM and Covaxin® on mortality among symptomatic COVID-19 patients during the second wave of the pandemic in South India during April and May 2021: a cohort study. Vol. 40, Vaccine. 2022. p. 2107–13.

Citation

Copyright

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Article metrics

Google scholar: See link

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Most read articles

Indexed by
DOAJ
Google Scholar
ERIHPLUS
MIAR I
Crossref